St. John’s-based disinfectant maker Polyamyna Nanotech has inked a deal with Eastern Health to run clinical trials of its product once it receives Health Canada approval.
Polyamyna, which graduated from the Genesis Evolution program in January, says its disinfectant has been proven by third-party testing to kill antimicrobial-resistant pathogens, sometimes called “superbugs.” It can be used to coat surfaces, reducing the need for reapplications.
“Our main focus is to build a new antimicrobial technology to counter superbugs, because right now, we are seeing a variety of superbugs,” said CTO
